These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 19490731

  • 1. Early CD44(hi)CD4+ and CD44(hi)CD8+ T cell numbers and the absence of mannose-rich glycoconjugates determine the protective outcome of anti-leishmanial immunity.
    Kedzierski L, Curtis JM, Kedzierska K.
    Parasitology; 2009 Jul; 136(8):833-40. PubMed ID: 19490731
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge.
    Okwor I, Kuriakose S, Uzonna J.
    Vaccine; 2010 Jul 26; 28(33):5451-7. PubMed ID: 20558242
    [Abstract] [Full Text] [Related]

  • 5. Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis.
    Okwor I, Liu D, Uzonna J.
    Vaccine; 2009 Apr 28; 27(19):2554-62. PubMed ID: 19428861
    [Abstract] [Full Text] [Related]

  • 6. Leishmania major MAP kinase 10 is protective against experimental L. major infection.
    Kumari S, Singh S, Saha B, Paliwal PK.
    Vaccine; 2011 Nov 08; 29(48):8783-7. PubMed ID: 21527301
    [Abstract] [Full Text] [Related]

  • 7. Cross-talk between CD8(+) and CD4(+) T cells in experimental cutaneous leishmaniasis: CD8(+) T cells are required for optimal IFN-gamma production by CD4(+) T cells.
    Herath S, Kropf P, Müller I.
    Parasite Immunol; 2003 Nov 08; 25(11-12):559-67. PubMed ID: 15053777
    [Abstract] [Full Text] [Related]

  • 8. Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice.
    Remer KA, Apetrei C, Schwarz T, Linden C, Moll H.
    Eur J Immunol; 2007 Sep 08; 37(9):2463-73. PubMed ID: 17705130
    [Abstract] [Full Text] [Related]

  • 9. CD8 alpha- and Langerin-negative dendritic cells, but not Langerhans cells, act as principal antigen-presenting cells in leishmaniasis.
    Ritter U, Meissner A, Scheidig C, Körner H.
    Eur J Immunol; 2004 Jun 08; 34(6):1542-50. PubMed ID: 15162423
    [Abstract] [Full Text] [Related]

  • 10. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.
    Gurunathan S, Stobie L, Prussin C, Sacks DL, Glaichenhaus N, Iwasaki A, Fowell DJ, Locksley RM, Chang JT, Wu CY, Seder RA.
    J Immunol; 2000 Jul 15; 165(2):915-24. PubMed ID: 10878366
    [Abstract] [Full Text] [Related]

  • 11. Targeted activation of CD8 cells and infection of beta 2-microglobulin-deficient mice fail to confirm a primary protective role for CD8 cells in experimental leishmaniasis.
    Wang ZE, Reiner SL, Hatam F, Heinzel FP, Bouvier J, Turck CW, Locksley RM.
    J Immunol; 1993 Aug 15; 151(4):2077-86. PubMed ID: 8102158
    [Abstract] [Full Text] [Related]

  • 12. LACK-reactive CD4+ T cells require autocrine IL-2 to mediate susceptibility to Leishmania major.
    Gumy A, Aseffa A, Rachinel N, Breton M, Otten L, Tacchini-Cottier F, Röcken M, Doyen N, Acha-Orbea H, Locksley RM, MacDonald HR, Launois P, Louis J.
    Eur J Immunol; 2006 Jun 15; 36(6):1465-73. PubMed ID: 16637008
    [Abstract] [Full Text] [Related]

  • 13. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites.
    Zaph C, Uzonna J, Beverley SM, Scott P.
    Nat Med; 2004 Oct 15; 10(10):1104-10. PubMed ID: 15448686
    [Abstract] [Full Text] [Related]

  • 14. Life-long systemic protection in mice vaccinated with L. major and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes.
    Gabaglia CR, Sercarz EE, Diaz-De-Durana Y, Hitt M, Graham FL, Gauldie J, Braciak TA.
    Vaccine; 2004 Nov 25; 23(2):247-57. PubMed ID: 15531044
    [Abstract] [Full Text] [Related]

  • 15. An in silico immunological approach for prediction of CD8+ T cell epitopes of Leishmania major proteins in susceptible BALB/c and resistant C57BL/6 murine models of infection.
    Guerfali FZ, Ben-Abdallah H, Sghaier RM, Ben-Aissa K, Mkannez G, Attia H, Laouini D.
    Infect Genet Evol; 2009 May 25; 9(3):344-50. PubMed ID: 18420466
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
    Ramírez L, Santos DM, Souza AP, Coelho EA, Barral A, Alonso C, Escutia MR, Bonay P, de Oliveira CI, Soto M.
    Vaccine; 2013 Feb 18; 31(9):1312-9. PubMed ID: 23313653
    [Abstract] [Full Text] [Related]

  • 17. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L.
    Vaccine; 2007 May 22; 25(21):4159-69. PubMed ID: 17395340
    [Abstract] [Full Text] [Related]

  • 18. Major role for CD8 T cells in the protection against Toxoplasma gondii following dendritic cell vaccination.
    Guiton R, Zagani R, Dimier-Poisson I.
    Parasite Immunol; 2009 Oct 22; 31(10):631-40. PubMed ID: 19751475
    [Abstract] [Full Text] [Related]

  • 19. Abrogation of CCL21 chemokine function by transgenic over-expression impairs T cell immunity to local infections.
    Unsoeld H, Mueller K, Schleicher U, Bogdan C, Zwirner J, Voehringer D, Pircher H.
    Int Immunol; 2007 Nov 22; 19(11):1281-9. PubMed ID: 17914120
    [Abstract] [Full Text] [Related]

  • 20. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells.
    Resende DM, Caetano BC, Dutra MS, Penido ML, Abrantes CF, Verly RM, Resende JM, Piló-Veloso D, Rezende SA, Bruna-Romero O, Fernandes AP, Gazzinelli RT.
    Vaccine; 2008 Aug 18; 26(35):4585-93. PubMed ID: 18588933
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.